Sarepta Therapeutics, Inc., a Cambridge, Massachusetts-based biopharmaceutical company, has dedicated itself to the development and discovery of RNA-targeted therapeutics, genetic therapeutic modalities, and gene therapies to tackle rare diseases. The company has a proven track record with the development of EXONDYS 51 injection to remedy Duchenne muscular dystrophy (Duchenne) in patients who have a confirmed mutation in their dystrophin gene which is amenable to exon 51 skipping. Additionally, Sarepta Therapeutics offers VYONDYS 53, which treats Duchenne in patients who had a confirmed mutation in the dystrophin gene that is amenable to exon 53 skipping, as well as AMONDYS 45 for Duchenne patients confirmed to have a dystrophin gene mutation. Moreover, the company is continuously working towards the development of more novel therapies with its current research, such as SRP-5051 (a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA), SRP-9001 (a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial), and SRP-9003, a limb-girdle muscular dystrophies gene therapy program, among others. Sarepta Therapeutics has collaborated with well-known organizations such as F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Genevant Sciences, University of Florida, Dyno Therapeutics, Selecta Biosciences, Hansa Biopharma, Lysogene, Duke University, Genethon, and StrideBio to further its efforts. The company has been in operation since 1980 and has grown significantly over the years.
Sarepta Therapeutics's ticker is SRPT
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 201-500 employees working at Sarepta Therapeutics
It is sarepta.com
Sarepta Therapeutics is in the Healthcare sector
Sarepta Therapeutics is in the Biotechnology industry
The following five companies are Sarepta Therapeutics's industry peers: